ArticleBioengineering (Basel, Switzerland)2025
Mitomycin C in Ahmed Glaucoma Valve Implant Affects Surgical Outcomes.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Long-Term Intraocular Pressure-Lowering and Antifibrotic Effects of a Biodegradable HA-Mg Glaucoma Drainage Implant in a Chronic Glaucoma Rabbit Model.Translational vision science & technology · 2026Article
- Current Challenges of Managing Fibrosis Post Glaucoma Surgery and Future Perspectives.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Glaucoma is the leading cause of irreversible blindness worldwide, and the Ahmed Glaucoma Valve (AGV) implant is one of the most commonly performed surgeries to prevent glaucoma-related visual impairment. Mitomycin C is an anti-fibrotic agent that may prevent failure of AGV. This is a retrospective case-control study to evaluate surgical outcomes for patients undergoing AGV with adjunct mitomycin C (MMC) injections compared to those without MMC. Among the 142 eyes, 50 received adjunct MMC compared to 92 without MMC injections. IOPs at post-operative months 1, 3, and 6 were significantly lower in the MMC eyes (9.40, 12.01, 12.63 mmHg) compared to the No-MMC eyes (16.86, 15.87, 15.65 mmHg;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.